| Overview |
| bs-0031R-Cy5 |
| BTG2 Polyclonal Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse |
| Rat, Pig, Rabbit, Guinea Pig |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human BTG2 |
| 31-110/158 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7832 |
| P78543 |
| Secreted |
| BTG2_HUMAN; Protein BTG2; BTG family member 2; NGF-inducible anti-prolerative protein PC3; pheochromacytoma cell-3; nerve growth factor-inducible anti-prolerative; B-cell translocation gene 2; BTG2; TIS21; PC3; TIS21. |
| BTG2 is a member of the BTG/Tob family. This family has structurally related proteins that appear to have antiproliferative properties. BTG2 is involved in the regulation of the G1/S transition of the cell cycle. It modulates transcription regulation mediated by ESR1(referenced from Entrez Gene). BTG2 expression is induced in vivo during neurogenesis, and the gene is transiently expressed in vitro in rat pheochromocytoma PC12 cells after induction of neuronal differentiation by addition of nerve growth factor (NGF); suggesting that BTG2 is functionally significant during the neuronal differentiation process (PMID: 12360398). |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz